Research and Markets: Baxter International 2013 Company Report

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c27564/baxter) has announced the addition of the "Baxter International Medical Device Company Intelligence Report" report to their offering.

“Baxter International Medical Device Company Intelligence Report”

Baxter International Inc develops, manufactures and markets products for the treatment of haemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The company applies a combination of expertise in medical devices, pharmaceuticals and biotechnology.

Prior to 2011, Baxter operated under three business segments: BioScience, Medication Delivery and Renal. As of 1st January 2011, the company combined its Medication Delivery and Renal businesses into a single global business unit to form the Medical Products business.

In December of 2012, Baxter entered into a definitive agreement to acquire privately-held Gambro, for total consideration approximately US$4.0 billion. Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The acquisition will give Baxter a comprehensive dialysis product portfolio, complementing its existing home dialysis offerings.

It is believed that the transaction will provide a number of long-term growth opportunities for Baxter worldwide. With a broad and complementary dialysis product portfolio, Baxter can accelerate product sales in established markets such as Europe, where Gambro has an extensive footprint. Baxter can also expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis business. In addition, Baxter will also build upon its pipeline of investigational home haemodialysis and automated PD systems with the addition of Gambro's monitors, dialysers, devices and dialysis systems.

In January 2012, Baxter rejected an unsolicited mini-tender offer by TRC Capital Corporation to purchase up to two million shares, or approximately 0.35%, of Baxter's outstanding common stock at a price of US$46.10 per share in cash. The offer price was 4.67% below the US$48.36 closing price of Baxter's common stock on 15th December 2011, the day prior to the offer.

In Business Monitor International's list of top ten US medical device manufacturers 2006-2011, Baxter was ranked in fourth position, behind Johnson & Johnson, GE and Medtronic. This profile primarily concentrates on Baxter's medical device activities.

Key Topics Covered

Overview

- Key contact information

- Introduction to the company and its current activities

- Summary of its financial performance

- Who are the company's major competitors?

- Key recent events in an at a glance format

Financial Review

- Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)

- Table providing in-depth five-year financial analysis

- Employee data, including breakdown by company division and geographic location

Strategic Focus